Skip to Navigation
Skip to Main Content
Skip to Related Content

Advertisement

U.S. Markets closed

S&P 500
5,851.20
-2.78(-0.05%)
Dow 30
42,924.89
-6.71(-0.02%)
Nasdaq
18,573.13
+33.12(+0.18%)
Russell 2000
2,231.53
-8.18(-0.37%)
Crude Oil
72.24
+0.15(+0.21%)
Gold
2,761.40
+1.60(+0.06%)

How do you feel about Elon Musk's alliance with Donald Trump? Take our poll.

Novo Nordisk A/S (NVO)

NYSE - Nasdaq Real Time Price. Currency in USD

Follow

Visitors trend2W10W9M

116.47

-0.86

(-0.73%)

At close: 04:00PM EDT

116.41

-0.06

(-0.05%)

After hours:

06:19PM EDT

Trade prices are not sourced from all markets

Previous Close	117.33
Open	115.00
Bid	116.49 x 1000
Ask	116.44 x 1000
Day's Range	114.76 - 116.65
52 Week Range	92.94 - 148.15
Volume	4,685,876
Avg. Volume	3,928,878

Market Cap	519.951B
Beta (5Y Monthly)	0.15
PE Ratio (TTM)	39.89
EPS (TTM)	2.92
Earnings Date	Nov 06, 2024
Forward Dividend & Yield	1.45 (1.23%)
Ex-Dividend Date	Aug 16, 2024
1y Target Est	143.05

All

Zacks
NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes Patients
A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients compared to placebo.
- Novo Nordisk plans label expansion for Rybelsus following Phase III win
  Clinical Trials Arena
- Wegovy Maker Novo Nordisk's Oral Diabetes Pill Cuts Heart Attacks, Stroke Events By 14%
  Benzinga
Zacks
5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates
Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings.